Form 8-K - Current report:
SEC Accession No. 0001193125-24-280125
Filing Date
2024-12-17
Accepted
2024-12-17 08:16:57
Documents
16
Period of Report
2024-12-13
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d856941d8k.htm   iXBRL 8-K 29322
2 EX-10.1 d856941dex101.htm EX-10.1 40864
3 EX-99.1 d856941dex991.htm EX-99.1 8732
7 GRAPHIC g856941g1216163553183.jpg GRAPHIC 4921
  Complete submission text file 0001193125-24-280125.txt   225601

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA cycn-20241213.xsd EX-101.SCH 2857
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE cycn-20241213_lab.xml EX-101.LAB 18738
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE cycn-20241213_pre.xml EX-101.PRE 11712
18 EXTRACTED XBRL INSTANCE DOCUMENT d856941d8k_htm.xml XML 3757
Mailing Address 301 BINNEY STREET CAMBRIDGE MA 02142
Business Address 301 BINNEY STREET CAMBRIDGE MA 02142 617-621-7722
Cyclerion Therapeutics, Inc. (Filer) CIK: 0001755237 (see all company filings)

EIN.: 831895370 | State of Incorp.: MA | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38787 | Film No.: 241553713
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)